Millions of heart disease patients fall into a diagnostic no-man's land — their cardiac function is too preserved to qualify for a defibrillator under current guidelines, yet not healthy enough to be free of sudden death risk. The CMR GUIDE trial directly challenges whether the widely used 35% ejection fraction threshold is the right boundary for life-saving device therapy.
This multicenter randomized clinical trial enrolled 353 adults with ischemic or nonischemic cardiomyopathy, a left ventricular ejection fraction (LVEF) between 36% and 50%, and CMR-confirmed myocardial scar — all while on guideline-directed medical therapy. Conducted across 18 sites in Australia, Germany, and the UK from 2015 to 2022 with follow-up through 2026, patients were randomly assigned to either a primary prevention implantable cardioverter-defibrillator (ICD) or an implantable loop recorder (ILR) for monitoring only. Notably, 70% of participants had an LVEF of 40% or greater, placing them squarely in territory where no current guideline supports routine ICD implantation. The primary composite endpoint was sudden cardiac death or hemodynamically significant ventricular arrhythmia.
The significance of this trial extends well beyond its enrollment numbers. Current ICD eligibility criteria — anchored to an LVEF threshold of ≤35% — emerged from landmark trials conducted in the 1990s and early 2000s when advanced cardiac imaging was not routinely integrated into risk stratification. The biological rationale for scar-guided selection is compelling: myocardial fibrosis detected by late gadolinium enhancement on CMR is an established substrate for re-entrant arrhythmia, independent of ejection fraction. Several observational cohorts have linked scar burden to arrhythmic events even when LVEF is relatively preserved, but randomized evidence has been absent until now. If the CMR GUIDE results demonstrate a meaningful reduction in arrhythmic events in the ICD arm, they could reframe patient selection criteria and bring a broader population into preventive device therapy — a potentially paradigm-shifting shift in how cardiologists use imaging to allocate risk. Key limitations include the open-label design, a predominantly male and ischemic cohort, and the relatively modest sample size for a device outcomes trial.